LEO Pharma announces NDA submission of first aerosol foam formulation for plaque psoriasis

LEO Pharma announces it has submitted a New Drug Application (NDA) for calcipotriene and betamethasone dipropionate aerosol foam, 0.005%/0.064%, to the U.S. Food and Drug Administration (FDA) for the treatment of plaque psoriasis.



from The Medical News http://ift.tt/1De3FiR